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Drugs, Bugs, and Esophageal pH Profiles
Malcolm Robinson
University ofOklahoma College ofMedicine, Oklahoma City, Oklahoma
Until relatively recently, gastroesophageal reflux disease (GERD) was thought to be a relatively
trivialproblem, andpharmaceutical companies initially hadremarkably little interest in clinical tri-
alsfor GERD. Over the last ten years, GERD therapy has become the subject ofintense interest,
since reflux disease is now recognized as a major marketfor antisecretory andprokinetic drugs.
Even low-technology antacids are now known to effectively neutralize esophageal acidpreventacid
refluxfor up to 90 minutes. EsophagealpHprofiling is known to be an excellent surrogatefor clin-
ical efficacy ofGERD drugs, particularly in erosive esophagitis. Years ago,famotidine normalized
esophageal mucosal exposure to pH < 4.0 only when administered in doses of40 mg twice a day.
Subsequent studies confirmed that multiple daily dosing of histamine-2 receptor antagonists
(H2RAs) was mandatory for GERD treatment, with clear dose-response relationships for each
agent.
Proton pump inhibitors (PPIs) have each been carefully assessed in terms esophageal and gastric
pHprofiles. Omeprazole has aparticularlyflat dose response curve, making it difficult to differen-
tiatepHorclinical effects of20 vs. 40mg doses. Improvedrapidity ofonsetand/orenhancedpoten-
cy is demonstrable inpHdata obtainedwith lansoprazole, rabeprazole andpantoprazole. Such dif-
ferences will translate to improved clinical efficacy, based on the meta-analyses ofRichard Hunt
and his group in Canada that correlate pH effects and symptom relief/healing. PPIs have depend-
ably surpassedH2RAs andprokinetic drugs in management ofthe more severe grades ofesophagi-
tis.
Helicobacterpylori has apeculiar relationship to GERD. There has been some concern that PPIs
given topatients with H. pylori might accelerate development ofsevere atrophic gastritis. It is also
now known that eradication ofH. pylori may increase symptomatic GERD (possibly as a result of
increased gastric acid secretion once the bacteria have been eliminated).
New data confirm nocturnal breakthrough ofacidsecretion andesophageal acid exposure in three-
fourths ofpatients on omeprazole 20 mg twice daily. This nocturnal acidity can be controlled more
effectively with a nighttime dose ofan H2RA than with a third dose ofomeprazole.
Control ofacid secretion and improved gastric and esophageal pHprofiles are goals ofmodern
GERD therapy, and theproduct thatmost costeffectively normalizes esophageal acidexposure will
have a substantial advantage in the ever-growing GERD marketplace.
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In 1935, Asher Winkelstein [1] first
described gastroesophageal reflux disease
in its present guise. His paper in the
Journal of the American Medical
Association reviewed five cases that he
described as "peptic esophagitis" with
damage to the esophageal mucosa attrib-
uted to the reflux ofcorrosive acidic diges-
tivejuices. The existence ofthis condition
was not widely accepted for many years.
Along with many physicians, otherwise
sagacious pharmaceutical executives intro-
ducing anti-secretory drugs argued that
their "market" was for treatment of
"ulcers." Gastroesophageal reflux disease
(GERD)b was thought to be a relatively
trivial problem, and there was remarkably
little effort to initiate early trials of antise-
cretory agents for this entity. When the
Barbican meeting in London launched
ranitidine (Zantac) almost 20 years ago,
the session on GERD accounted for only
15 minutes of an extensive three-day sci-
entific program.
Earlier in the history ofthe histamine-
2 receptor antagonists (H2RAs), a distin-
guished group of esophagologists includ-
ing Sidney Cohen and Donald Castell pur-
sued the potential use of cimetidine
(Tagamet) for GERD [2]. Despite some
evidence for symptomatic relief of heart-
burn, this large U.S. multicenter trial of
cimetidine for GERD failed to document
healing of erosive esophagitis. Ranitidine
trials involving GERD patients were
almost an afterthought in a development
program heavily weighted toward the
treatment of duodenal and gastric ulcers.
Despite patient selection that enrolled rel-
atively few erosive esophagitis cases,
almost precluding demonstration of
esophagitis healing, slightly more of the
erosive cases healed with ranitidine than
with placebo [3]. Based on this tenuous
finding, Glaxo developed an eventual near
marketing stranglehold for ranitidine in
this highly productive arena of product
sales. Many billions of dollars have been
garnered in the GERD market. Glaxo was
most successful among purveyors of
H2RAs, followed at lesser sales levels by
Eli Lilly (Axid), Merck (Pepcid) and
Smith-Kline-Beecham (Tagamet). It
seems clear that unparalleled successes in
sales of anti-secretory and prokinetic
drugs for GERD have led to large numbers
ofclinical investigations and massive rele-
vant literature. Esophageal pH profiling
has included studies with each ofthe drugs
marketed for GERD, and such studies
have clearly demonstrated the correlation
of clinical efficacy with 24-hr esophageal
mucosal exposure to pH < 4.0.
Not surprisingly, the major clinical
trial thrust of Merck (later Astra Merck)
for the first proton pump inhibitor (PPI),
omeprazole (Losec renamed Prilosec)
involved GERD. As time has passed, each
new proton pump inhibitor (lansoprazole,
pantoprazole and rabeprazole) has focused
major clinical trials on GERD with rela-
tively modest efforts directed toward the
treatment of duodenal and gastric ulcers
and other indications. Careful studies of
each new PPI have addressed both gastric
and esophageal pH effects as part of the
dose selection process. The overall GERD
market in the Western world remains vast,
seemingly continuing to grow endlessly.
It is now widely recognized that the
pathophysiology of GERD involves
deranged esophageal motility with
increased transient lower esophageal relax-
ations and/or deficient basal lower
esophageal sphincter tone, impaired
esophageal acid clearance, and occasional-
ly impaired gastric emptying. Although
prokinetic therapy can be helpful in mild
GERD, more advanced esophageal mucos-
al damage can only be managed with acid
suppression. Richard Hunt and his col-
leagues at McMaster University have
demonstrated a very high correlation
between degree ofacid inhibition and heal-
ing of erosive damage to the esophageal
mucosa as well as control ofreflux-related
symptoms [4]. Therefore, although H2RAs
andprokinetic medications canbe extreme-
ly satisfactory for control of heartburn,
PPIs uniformly surpass even ultra-highRobinson: Drugs, bugs andpHprofiles 171
doses of H2RAs or the combination of
H2RA's with prokinetic medications for
treating the more severe endoscopic grades
oferosive esophagitis.
Antacids, considered archaic by many
physicians, are actually surprisingly effec-
tive at promptly elevating esophageal pH
and continuing to neutralize acid at the
esophageal mucosal level for up to 90 min
after dosing [5]. There is currently great
interest in the development of suitable
H2RA-antacid combinations to allow both
the prompt treatment of heartburn as well
as the prevention of subsequent heartburn
episodes for many hours. No such combi-
nation product currently exists, but the
growing over-the-counter market for low-
dose or even prescription-level H2R's will
stimulate further ambitious development
of effective and reliable chewable formu-
lations of antacids and H2RAs.
Helicobacter pylori has been a major
scientific focus in gastroenterology for the
last several years, and it is clear that most
"peptic" ulcers can be attributed to gastric
mucosa infected with H. pylori. However,
at least at the present time, there appears to
be no causal relationship between H.
pylori and GERD. Indeed, there is some
evidence that the effective eradication of
H. pylori, a known inhibitorofgastric acid
secretion, may worsen the symptoms of
gastroesophageal reflux following gastric
or duodenal ulcer healing and bacterial
eradication. A fascinating controversy
arose over the past two years in relation to
the development of chronic atrophic gas-
tritis following long-term PPI therapy of
GERD. Ernst Kuipers' important 1996
article in the New England Journal of
Medicine suggested that Dutch GERD
patients infected with H. pylori receiving
omeprazole maintenance treatment devel-
oped accelerated atrophic gastritis versus a
group of Swedish patients who had been
managed surgically [6]. Subsequently, it
has become clear that the control group
may not have been perfectly matched to
the medically treated patients; and an
FDA-sponsored consensus conference has
disputed the relationship between PPI
therapy and development of chronic
atrophic gastritis. Indeed, careful review of
omeprazole and lansoprazole maintenance
therapy data by both current PPI sponsors
thus far has failed to substantiate any link-
age between PPI treatment and any chron-
ic gastric atrophy. Nevertheless, since H.
pylori itself can lead to chronic atrophic
gastritis, discussions of therapeutic
options continue.
It seems clear that there will now be
"PPI Wars" similar to the strong conflicts
between the various H2RAs that occurred
in the past. Omeprazole is now known to
be potentially variable in its metabolism,
and many patients fail to decrease patho-
logical esophageal acid exposure with
usual doses of omeprazole. Indeed, recent
data confirm that three-fourths of all
patients will have significant periods of
nocturnal acid exposure despite omepra-
zole 20 mg twice a day. Somewhat sur-
prising is the finding that this nocturnal
acid "breakthrough" responds better to a
bedtime dose of an H2RA vs. an addition-
al 20 mg of omeprazole [7]. Both panto-
prazole and rabeprazole seem to produce
more rapid onset and more complete gas-
tric acid inhibition than omeprazole, and
this differentiation seems sure to impact
future marketing. The precise levels of
dosing required for the newer PPIs have
yet to be determined, particularly as
applicable to refractory GERD patients.
Control ofesophageal pH may require
multiple doses ofall available PPIs, partic-
ularly in more difficult cases of GERD.
However, the PPI that can be most cost
effective will undoubtedly prosper in the
increasingly price-sensitive pharmaceuti-
cal market. In general, this will entail once
daily dosing for the majority of patients.
The PPI that can demonstrate such cost
effectiveness should gamer a substantial
marketing advantage.
In summary, it is clear that pH profil-
ing of antisecretory drugs in terms oftheir
effects on gastric and esophageal acidity
will continue to be critical to their posi-172 Robinson: Drugs, bugs andpHprofiles
tioning in the competitive marketplace,
and investigators working in this arena
should have much additional work ahead.
For GERD, the reduction of esophageal
acid exposure certainly can be considered
as a surrogate measure for clinical effica-
cy.
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